17-AAG
HSP90 inhibitor / Semi-synthetic analog of geldanamycin which is less toxic and more stable. Selectively binds to and inhibits HSP90 from tumor cells. Anti-angiogenic activity. Cell permeable.
Biochemicals & reagents
75747-14-7
Tanespimycin
1) Schulte et al., (1998), The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin; Cancer Chemother. Pharmacol. 42 273 / 2) Kamal et al., (2003), A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors; Nature 425 407 / 3) Kaur et al., (2004), Therapeutic and diagnostic implications of Hsp90 activation; Clinical Cancer Res. 10 4813
RT
TARGET: HSP (Heat shock protein); Antibiotic -- PATHWAY: Apoptosis inducer; Autophagy; Senescence -- RESEARCH AREA: Angiogenesis; Cell death; Ubiquitin/Proteasome; Cellular stress -- DISEASE AREA: Cancer; Infectious diseaseNeurodegeneration